Diagnos Inc., leader in diabetic retinopathy screening, is announcing the close of a commercial agreement to provide retina screening services to patients in the United States. The sponsor of the services is a major US-based pharmaceutical company that markets a leading ophthalmology product indicated for a variety of ophthalmic complications including those associated with diabetes.

“This second pharmaceutical contract provides additional validation of the clinical relevance and continuing market uptake of CARA, our proprietary diabetic retinopathy screening platform, to screen patients experiencing or at risk of vision complications, in order to address preventable clinical outcomes including blindness,” said Andre Larente, president of Diagnos. “Together with our other partners such as leading pharmaceutical companies, governments, nursing homes, and corporations, Diagnos is improving the quality of life of patients and minimizing the economic burden of vision problems around the world. We expect to continue putting into place additional nonexclusive agreements in the Unites States and in many other countries.”

There are millions of diabetic and pre-diabetic patients in the United States who do not routinely have their eyes screened for vision problems associated with diabetes. Diabetic retinopathy screening can make a major contribution towards improving their quality of life by identifying patients with unknown eye disorders and referring them for appropriate medical follow up.

As part of its mission to improve outcomes for patients, Diagnos’ client supports various high-impact health organizations and initiatives in the United States. The deployment of CARA is intended to slow or reverse vision impairment in the US diabetic patient population.

Diagnos is a publicly traded Canadian corporation with a mission to improve the quality of patients lives and minimize the economic burden of vision loss.